On January 9th, a California state appellate court surprisingly affirmed the creation of a novel corporate tort in the case Gilead Life Sciences, Inc. v. Superior Court of San Francisco. This decision holds a firm liable for negligence, not for creating a faulty product, but for failing to develop and market a superior product ahead of its existing offerings. This impressive reinterpretation of negligence can notably affect the product liability landscape.
In the case, Gilead Sciences Inc., the manufacturer of TDF, a treatment for HIV/AIDS, was sued by a class of 24,000 consumers. The unique aspect of this lawsuit was that the consumers were not alleging the product to be defective in nature, but that Gilead was negligent in not bringing a superior product to the market sooner. The claim is based on the premise that Gilead delayed the release of an allegedly better alternative to maximise sales of its existing product, thereby exposing the class members to prolonged harmful side effects.
Traditionally, negligence tort usually requires a demonstration to the jury that an injury due to a party’s failure to use reasonable care, resulting in an injury. In product liability cases, this typically includes showing defective manufacturing or design, or a negligent omission of warnings pertaining to potential dangers that consumers could otherwise avoid. Surprisingly, in this case, the class members acknowledged that TDF wasn’t defective notwithstanding the disclosed side effects. Instead, they accused Gilead of negligence on the grounds of deliberate delay in the development and sales of a safer product, leading to injuries from the prolonged side effects.
The unprecedented legal precedence set by the appellate court’s interpretation of negligence can potentially have a negative impact on the pharmaceutical industry and beyond. It exposes manufacturers to liability for any harmful side effects irrespective of FDA approval or proper consumer alert. The probable unnatural increase in the cost to cover such liabilities could slow down the introduction of new beneficial products in the market and adversely affect innovation scale.
Additionally, this novel tort puts critical corporate decisions, such as product development timelines, into the hands of lay juries. This has far-reaching implications not just for pharmaceuticals, as seen in the Gilead case, but also for other sectors, like automotive, where safety improves over time.
The shift of judgement from legislators, regulators, and corporations to juries as seen in this case represents a significant expansion of modern legal systems. It could deter innovation and slow down safety improvements in multiple industries. This circumstance calls for a critical review and balance in the system to ensure that progress is not stifly while safeguarding consumer interests.
For detailed analysis, kindly refer to the original article here.